FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949453019> ?p ?o ?g. }

• W2949453019 endingPage "409" @default.
• W2949453019 startingPage "409" @default.
• W2949453019 abstract "Background: Cold agglutinin disease (CAD) is a subtype of autoimmune hemolytic anemia in which cold-induced binding of antibodies directed against antigens on the erythrocyte surface cause hemolysis and anemia via complement activation. Sutimlimab is a novel, humanized monoclonal antibody directed against classical pathway complement factor C1 s. Aims: To evaluate the safety and efficacy of continuous long-term maintenance treatment with sutimlimab in patients with CAD. Methods: CAD patients treated with sutimlimab as part of a phase 1b study (Jaeger U et al; Blood 2019) were transitioned to a named patient program (NPP). After a loading dose, patients received bi-weekly infusions of sutimlimab at various doses. When a patient showed laboratory signs of breakthrough hemolysis, the dose of sutimlimab was increased. The data are censored by the inclusion of those patients into an open label extension of the original sutimlimab trial. Results: Seven patients with CAD participated in this NPP. Most of the patients had a prior history of multiple treatment failures and increased transfusion needs. Treatment duration with sutimlimab ranged from 2–21 months and doses were tailored to the specific individual patient's clinical and laboratory responses. Three patients started with a dose of 45 mg/kg, another three with 60 mg/kg and two patients with a fixed-dose of 5.5 g every other week. Sutimlimab infusions were well tolerated without need for premedication. All 7 patients responded to the drug. Effective complement inhibition was mirrored by a decrease in total complement activity CH50, increase in C4 levels and normalization of bilirubin. Sutimlimab infusions increased hemoglobin (Hb) from a mean initial level of 7.8 g/dL to a mean peak of 12.3 g/dL (p < 0.001). Patients maintained near normal Hb levels and inhibition of hemolysis for the duration of the study, except for few breakthrough events that were related to under-dosing and which were resolved after the appropriate dose increase. Five of the patients were eventually treated with 5.5 g of sutimlimab every 2 weeks. Of these, one had breakthrough hemolysis. This was consistent with PK/PD modeling showing a low but existent risk of decreased drug effect with this dose in certain individuals, thereby leading to the use of a higher dosing regimen for the pivotal trials. Two patients were removed from the NPP due to unrelated severe health conditions precluding use of a concurrent investigational drug (uterine cancer with active radiation, hydrocephalus with shunt implantation). One patient that was being treated with ibrutininb for lymphoplasmocytic lymphoma developed an infection-associated hemolytic crisis and was temporarily re-treated with sutimlimab. Initiation of sutimlimab treatment was associated with a rapid recovery to near normal Hb levels. All patients remained transfusion-free while on sutimlimab. There have been no serious adverse events related to this investigational drug. Summary/Conclusion: Long-term maintenance treatment with sutimlimab was safe, effectively inhibited hemolysis and significantly increased Hb levels in previously transfusion-dependent CAD patients. Classical complement blockade through C1 s inhibition may be an effective therapeutic target for continuous treatment of CAD patients over time. Doses higher than 5.5 g may be needed in some cases. Two phase 3 trials (NCT03347396, NCT03347422) evaluating the use of sutimlimab in primary CAD are currently underway." @default.
• W2949453019 created "2019-06-27" @default.
• W2949453019 creator A5002108877 @default.
• W2949453019 creator A5007985500 @default.
• W2949453019 creator A5011357281 @default.
• W2949453019 creator A5014879232 @default.
• W2949453019 creator A5015905526 @default.
• W2949453019 creator A5016366933 @default.
• W2949453019 creator A5018477126 @default.
• W2949453019 creator A5027524719 @default.
• W2949453019 creator A5031884367 @default.
• W2949453019 creator A5041859157 @default.
• W2949453019 creator A5050373396 @default.
• W2949453019 creator A5054050979 @default.
• W2949453019 creator A5075679908 @default.
• W2949453019 creator A5079106466 @default.
• W2949453019 creator A5083776642 @default.
• W2949453019 date "2019-06-01" @default.
• W2949453019 modified "2023-09-26" @default.
• W2949453019 title "S906 PRECLINICAL EVALUATION OF THE PRESERVATION OF RED BLOOD CELL CONCENTRATES IN HYPOXIA BY HYPOXIC STORAGE TECHNOLOGY FOR TRANSFUSION IN SICKLE CELL DISEASE." @default.
• W2949453019 doi "https://doi.org/10.1097/01.hs9.0000561904.90219.03" @default.
• W2949453019 hasPublicationYear "2019" @default.
• W2949453019 type Work @default.
• W2949453019 sameAs 2949453019 @default.
• W2949453019 citedByCount "0" @default.
• W2949453019 crossrefType "journal-article" @default.
• W2949453019 hasAuthorship W2949453019A5002108877 @default.
• W2949453019 hasAuthorship W2949453019A5007985500 @default.
• W2949453019 hasAuthorship W2949453019A5011357281 @default.
• W2949453019 hasAuthorship W2949453019A5014879232 @default.
• W2949453019 hasAuthorship W2949453019A5015905526 @default.
• W2949453019 hasAuthorship W2949453019A5016366933 @default.
• W2949453019 hasAuthorship W2949453019A5018477126 @default.
• W2949453019 hasAuthorship W2949453019A5027524719 @default.
• W2949453019 hasAuthorship W2949453019A5031884367 @default.
• W2949453019 hasAuthorship W2949453019A5041859157 @default.
• W2949453019 hasAuthorship W2949453019A5050373396 @default.
• W2949453019 hasAuthorship W2949453019A5054050979 @default.
• W2949453019 hasAuthorship W2949453019A5075679908 @default.
• W2949453019 hasAuthorship W2949453019A5079106466 @default.
• W2949453019 hasAuthorship W2949453019A5083776642 @default.
• W2949453019 hasBestOaLocation W29494530191 @default.
• W2949453019 hasConcept C126322002 @default.
• W2949453019 hasConcept C159654299 @default.
• W2949453019 hasConcept C203014093 @default.
• W2949453019 hasConcept C2778248108 @default.
• W2949453019 hasConcept C2778620579 @default.
• W2949453019 hasConcept C2779134260 @default.
• W2949453019 hasConcept C2779902561 @default.
• W2949453019 hasConcept C71924100 @default.
• W2949453019 hasConcept C90924648 @default.
• W2949453019 hasConcept C98274493 @default.
• W2949453019 hasConceptScore W2949453019C126322002 @default.
• W2949453019 hasConceptScore W2949453019C159654299 @default.
• W2949453019 hasConceptScore W2949453019C203014093 @default.
• W2949453019 hasConceptScore W2949453019C2778248108 @default.
• W2949453019 hasConceptScore W2949453019C2778620579 @default.
• W2949453019 hasConceptScore W2949453019C2779134260 @default.
• W2949453019 hasConceptScore W2949453019C2779902561 @default.
• W2949453019 hasConceptScore W2949453019C71924100 @default.
• W2949453019 hasConceptScore W2949453019C90924648 @default.
• W2949453019 hasConceptScore W2949453019C98274493 @default.
• W2949453019 hasIssue "S1" @default.
• W2949453019 hasLocation W29494530191 @default.
• W2949453019 hasLocation W29494530192 @default.
• W2949453019 hasOpenAccess W2949453019 @default.
• W2949453019 hasPrimaryLocation W29494530191 @default.
• W2949453019 hasRelatedWork W1524827063 @default.
• W2949453019 hasRelatedWork W2013062939 @default.
• W2949453019 hasRelatedWork W2018965817 @default.
• W2949453019 hasRelatedWork W2050153430 @default.
• W2949453019 hasRelatedWork W2065187314 @default.
• W2949453019 hasRelatedWork W2087166775 @default.
• W2949453019 hasRelatedWork W2467408034 @default.
• W2949453019 hasRelatedWork W2471743968 @default.
• W2949453019 hasRelatedWork W4288780957 @default.
• W2949453019 hasRelatedWork W4313626956 @default.
• W2949453019 hasVolume "3" @default.
• W2949453019 isParatext "false" @default.
• W2949453019 isRetracted "false" @default.
• W2949453019 magId "2949453019" @default.
• W2949453019 workType "article" @default.